The downgrade from Overweight to Neutral and the lowering of the price target from $95 to $85 by JP Morgan analyst Brian Essex indicates a less optimistic outlook for Okta's stock. This could lead to a short-term negative impact on the stock price as investors may adjust their positions based on the new rating and price target.